James McKay

This paper develops a polygenic score for smoking persistence and finds it is associated with earlier or later cessation ages across diverse populations.

The paper identifies lung cancer susceptibility copy number variants (CNVs) and shows their potential role in genomic instability through association analyses and functional validation.

This paper identifies shared genetic loci between inflammation and cancer risk using non-causal associations, revealing potential therapeutic targets.

The paper identifies functional variants and VNTRs at the 5p15.33 locus using fine-mapping, MPRA, and CRISPRi screens, revealing their role in cancer susceptibility through antagonistic pleiotropy.

This paper introduces a formal statistical replication analysis to reduce false positives in lung cancer GWAS, finding it significantly lowers false discovery rate and improves polygenic risk score efficiency.

This study identifies three novel germline variants associated with nasopharyngeal carcinoma risk and introduces a refined polygenic risk score linked to EBV infection.

The paper develops polygenic risk scores to stratify lung cancer and smoking cessation risk, showing significant odds ratios in diverse populations and planning clinical trials to evaluate interventions.

The paper identifies twelve novel genetic risk loci for lung cancer subtypes through multi-ancestry GWAS and shows smoking-independent genetic risk.

This study identifies 40 circulating proteins associated with cancer risk using MR and colocalization, highlighting potential therapeutic targets and adverse effects of protein-altering interventions.

This study investigates the relationship between genetically predicted leukocyte telomere length and lung cancer risk, finding a causal association and novel susceptibility loci.

This study identifies eight novel lung cancer susceptibility loci and shows that germline variants related to smoking and DNA repair influence somatic mutation burden in lung tumors.

The paper uses a genetic variant to assess cancer risk associated with TYK2 inhibition, finding increased risks for lung cancer and non-Hodgkin lymphoma.

This study identifies IL-18 as a biomarker for reduced lung cancer risk using genetic, pre-diagnostic, and tumor expression data, with potential therapeutic implications.

This study assesses polygenicity and risk prediction using common variants across 14 cancers, finding varying numbers of susceptibility variants and risk score effectiveness.

Needlestack is a variant caller that improves sensitivity for low abundance mutations by learning sequencing error rates from multi-sample data.

The paper identifies genetic links between impaired pulmonary function and increased lung cancer risk, showing causal relationships through Mendelian randomization and highlighting immune-related pathways.

The paper identifies a unique mutational signature of glycidamide, a metabolite of acrylamide, through experimental and computational analysis, linking it to cancer genome patterns.

This paper introduces a new pedigree analysis method to identify risk variants for complex diseases, applying it to Multiple Myeloma and finding two genes associated with DNA repair and chromatin remodeling.